ClinicalTrials.gg
Not yet recruitingNCT07753642Updated Aug 7, 2026

Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma

A Phase 2 interventional study of Golidocitinib and Doxorubicin in Nodal T-follicular Helper Cell Lymphoma, sponsored by Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with previously untreated nodal T-follicular helper (TFH) cell lymphoma.

02

Conditions studied

  • Nodal T-follicular Helper Cell Lymphoma
03

In context

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,692 studies on the registry; 620 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion Criteria:

  1. confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification.
  2. Previously untreated with systemic anti-lymphoma therapy.
  3. Age ≥18 and \<75 years.
  4. At least one measurable or evaluable lesion according to the Lugano 2014 criteria.
  5. An expected survival time of more than 12 weeks.
  6. An performance status score of 0-1.
  7. Adequate organ and bone marrow function.
  8. Provision of written and willingness to comply with all study procedures.

Key exclusion Criteria:

  1. Hemophagocytic syndrome.
  2. Central nervous system or meningeal involvement by lymphoma.
  3. Patients with a history of other within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin.
  4. Patients receiving potent inducers or inhibitors, vitamin K antagonists, antiplatelet agents, or anticoagulants.
  5. Patients with active infections, including tuberculosis, infection, active , or active .
  6. Patients with severe or uncontrolled cardiovascular disease.
  7. Patients with a history of interstitial lung disease, except for asymptomatic radiation-induced interstitial lung disease.
  8. Patients with gastrointestinal conditions that may interfere with oral administration or drug absorption.
  9. Patients with known to golidocitinib or its .
  10. Pregnant or breastfeeding women and participants of unwilling to use effective .
  11. Patients who have received systemic or other therapy within 14 days before the start of study treatment.
  12. Patients considered unsuitable for participation by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Golidocitinib Combined with Doxorubicin/Epirubicin

    Participants will receive golidocitinib 150 mg orally once daily in combination with either doxorubicin 50 mg/m² intravenously on Day 1 or epirubicin 60-90 mg/m² intravenously on Day 1 of each 21-day cycle for up to 6 cycles. Participants who achieve a complete response (CR) or partial response (PR) may receive golidocitinib monotherapy as maintenance treatment for up to 12 months, as determined by the investigator.

    Drug: Golidocitinib · Drug: Doxorubicin · Drug: Epirubicin

Interventions

06

What researchers measure

Primary outcomes

  1. Complete response rate

    Defined as the proportion of patients who achieve complete remission at the end of induction treatment.

    Time frame: Up to 6 cycles (each cycle is 21 days)

Secondary outcomes

  1. Progression-free survival(PFS)

    To investigate the preliminary anti-tumor efficacy.

    Time frame: From the date of enrollment until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

  2. Overall survival(OS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of death from ant cause, assessed up to 24 months

  3. Objective response rate (ORR)

    The proportion of patients who achieve complete remission (CR) or partial remission (PR)

    Time frame: Up to 6 cycles (each cycle is 21 days)

  4. Duration of Response(DOR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: The time from the patient's first efficacy assessment achieving CR or PR until disease progression, assessed up to 24 months

  5. Adverse events

    The incedence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

    Time frame: Up to 28 days after the last dose of study treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 7, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 30, 2029
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07753642
Responsible party
Qingqing Cai (Principal Investigator, Sun Yat-sen University) — Principal investigator
First posted
Aug 7, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Aug 7, 2026

Study contacts

Qingqing Cai, MD. PhD.
Contact
caiqq@sysucc.org.cn
02087342823

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion